First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

Recruiting

Phase 1

VNT-101First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT07169318

Conditions

Influenza

Eligibility Criteria

Sex: All

Age: 18 - 59

Healthy Volunteers: Accepted

Interventions

Placebo for VNT-101

VNT-101

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-30. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2025-11-14.